Q-omics provides the consensus-scored KRT18P56 profile across patient tissues and cancer cell-line models. KRT18P56 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KRT18P56 is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, KRT18P56 RNA expression shows 4,802 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LUAD, STAD, and ESCA as cancer lineages where KRT18P56 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P56 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P56 survival associations across molecular data types. KRT18P56 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P56 RNA expression–survival associations across cancer types. High KRT18P56 expression shows unfavorable associations in LUAD, HNSC, MESO, THYM, ACC and STAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KRT18P56 RNA expression.
This table summarizes KRT18P56 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P56. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P56 shows lower tumor expression in KIRC and PAAD and higher tumor expression in STAD, BRCA and LIHC. The STAD box plot shows higher KRT18P56 RNA expression in tumor versus normal tissue (log2 FC = +0.181, t-test p = .003).
This table shows molecular features associated with KRT18P56 in patient tissues and cancer cell lines. In patient samples, KRT18P56 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
